Published • loading... • Updated
Corsair Pharma Announces Positive Phase 1 Results for the TRX-248 Transdermal System in Pulmonary Arterial Hypertension
Summary by HealthTech HotSpot
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
Corsair Pharma Announces Positive Phase 1 Results for the TRX-248 Transdermal System in Pulmonary Arterial Hypertension
Favorable results support advancement into further clinical developmentNEWARK, Calif.--(BUSINESS WIRE)--Corsair Pharma, Inc., a private biopharmaceutical company, today announced the successful completion of its first-in-human Phase 1 clinical trial evaluating the TRX-248 Transdermal System, a once-daily transdermal patch designed for the treatment of pulmonary arterial hypertension (PAH). The positive results demonstrated that the TRX-248 Trans…
Father's Day SaleGet 40% off Vantage subscriptions for yourself or a friend.Get Started
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
